(Q44153213)

English

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

scientific article published on 17 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer (English)

1 reference

Europe PubMed Central

30 November 2017

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

30 November 2017

Sandra M. Swain

9

1 reference

Europe PubMed Central

30 November 2017

2

object named as

J Baselga

1 reference

Europe PubMed Central

30 November 2017

author name string

Y-H Im

3

1 reference

Europe PubMed Central

30 November 2017

S-A Im

4

1 reference

Europe PubMed Central

30 November 2017

X Pivot

5

1 reference

Europe PubMed Central

30 November 2017

G Ross

6

1 reference

Europe PubMed Central

30 November 2017

E Clark

7

1 reference

Europe PubMed Central

30 November 2017

A Knott

8

1 reference

Europe PubMed Central

30 November 2017

publication date

17 July 2013

1 reference

Europe PubMed Central

30 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

30 November 2017

24

1 reference

Europe PubMed Central

30 November 2017

10

1 reference

Europe PubMed Central

30 November 2017

2630-2635

1 reference

Europe PubMed Central

30 November 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Oncologists' use of quality of life information: results of a survey of Eastern Cooperative Oncology Group physicians.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Exploration of oncologists' attitudes toward and perceived value of patient-reported outcomes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Identifiers

10.1093/ANNONC/MDT274

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44153213&oldid=2107209103"